Dupilumab approved for use in eczema patients in Singapore, but treatment is costly

Atopic dermatitis, also known as atopic eczema, is the most common form of eczema, a skin inflammation characterised by a red, inflamed and itchy rash. About 10 to 11 per cent of the adult population in Singapore are estimated to have atopic eczema.
Atopic dermatitis, also known as atopic eczema, is the most common form of eczema, a skin inflammation characterised by a red, inflamed and itchy rash. About 10 to 11 per cent of the adult population in Singapore are estimated to have atopic eczema. PHOTO: ISTOCKPHOTO
More than a third of patients who used biologic drug Dupilumab for treatment for atopic dermatitis (pictured) had clear to almost clear skin after four months, during trial tests.
More than a third of patients who used biologic drug Dupilumab for treatment for atopic dermatitis (pictured) had clear to almost clear skin after four months, during trial tests.PHOTO: NATIONAL SKIN CENTRE

SINGAPORE - A newly approved first-of-its-kind biologic drug may bring hope to patients who are having a hard time bringing their moderate to severe atopic eczema under control.

Some patients at both public and private institutions, including adolescents, have been treated with the newly available Dupilumab, sold under the brand name Dupixent, which has been shown to be relatively safe and effective in international trials that included Singapore. The Health Sciences Authority approved its use in adult patients about two months ago.

Please or to continue reading the full article. Learn more about ST PREMIUM.

Enjoy unlimited access to ST's best work

  • Exclusive stories and features on multiple devices
  • In-depth analyses and opinion pieces
  • ePaper and award-winning multimedia content